Table 2.
Morbidity conditions in the audited sample of women with PLTC and SMO, ACSH, 1 July 2018–30 June 2019.
| Morbidity conditions | N | % |
|---|---|---|
| Women with PLTC | 691 | 100 |
| Women with severe complications | ||
| Severe postpartum hemorrhage | 166 | 24.0 |
| Severe preeclampsia | 303 | 43.8 |
| Eclampsia | 46 | 6.7 |
| Sepsis or severe systemic infection | 130 | 18.8 |
| Uterine rupture | 22 | 3.2 |
| Women undergoing critical interventions | ||
| Use of blood products | 256 | 37.0 |
| Laparotomy | 70 | 10.1 |
| Admission to ICU | 24 | 3.5 |
| Organ dysfunction in mothers with SMO | ||
| Cardiovascular dysfunction | 144 | 84.7 |
| Respiratory dysfunction | 76 | 44.7 |
| Renal dysfunction | 14 | 8.2 |
| Coagulation/hematologic dysfunction | 15 | 8.8 |
| Hepatic dysfunction | 6 | 3.5 |
| Neurologic dysfunction | 2 | 1.2 |
| Uterine dysfunction/hysterectomy | 26 | 15.3 |
| Multiple organ dysfunction | 89 | 52.4 |
| Organ dysfunction in maternal deaths | ||
| Cardiovascular dysfunction | 22 | 91.7 |
| Respiratory dysfunction | 19 | 79.7 |
| Renal dysfunction | 10 | 37.5 |
| Uterine dysfunction/hysterectomy | 2 | 8.3 |
| Coagulation/hematologic dysfunction | 1 | 4.2 |
| Hepatic dysfunction | 1 | 4.2 |
| Neurologic dysfunction | 1 | 4.2 |
PLTC: potentially life-threatening conditions; SMO: severe maternal outcome; ACSH: Ayder Comprehensive Specialized Hospital.